Your selections:
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan
Colony stimulating factor-1 receptor as a target for small molecule inhibitors
- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie K.
Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants
- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie
Expression of biologically active human colony stimulating factor-1 in Pichia pastoris
- Mashkani, Baratali, Odell, Adam F., Byrnes, Ellen M., Griffith, Renate, Ashman, Leonie K.
FMS-like tyrosine kinase 3 (FLT3) inhibitors: molecular docking and experimental studies
- Mashkani, Baratali, Tanipour, Mohammad Hossein, Saadatmandzadeh, Mohammad, Ashman, Leonie K., Griffith, Renate
Hybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting
- Farokhimanesh, Samila, Rahbarizadeh, Fatemah, Rasaee, Mohammad J., Kamali, Abbas, Mashkani, Baratali
MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1
- Kim, Kyu-Tae, Carroll, Adam P., Mashkani, Baratali, Cairns, Murray J., Small, Donald, Scott, Rodney J.
Small molecule inhibitors for type III receptor tyrosine kinases
Are you sure you would like to clear your session, including search history and login status?